Article Text

Download PDFPDF
CMT2CC associated with NEFH mutations: a predominantly motor neuronopathy

Statistics from Altmetric.com

Footnotes

  • Contributors CP and DP contribution: conception and design of the work, drafting the work, final approval of the version to be published; agreement for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Disclaimer CP has no disclosure to report.

  • Competing interests DP declares donations from Pfizer, LAM Therapeutics and Acceleron to support research activities of his research unit; financial support from Pfizer, Alnylam and Kedrion for participation in national and international meetings; participation in the advisory board of Inflectis, Alnylam and Akcea; speaker honorarium from Alnylam.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles